Articles by Charlotte Robinson
Study results suggest that psychosocial interventions effectively reduce depression symptoms in people with CKD.
Meta-analyses reaffirmed cardiovascular and renal benefits of long-acting GLP-1RAs for patients with type 2 diabetes.
Variability in eGFR over time is associated with risks of cardiovascular and kidney outcomes and mortality in those with CKD.
An observational study shed light on how family medical history may affect chronic kidney disease (CKD) outcomes.
A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline.
The FDA has granted Orphan Drug Designation to veverimer for anti–glomerular basement membrane (anti-GBM) disease.
Fibrate use is associated with higher incidence of CKD but lower risk for ESKD and mortality, a study found.
Iron therapy may reduce cardiovascular risks for patients with chronic kidney disease, a study found.
Rajiv Agarwal discussed a study showing that a finerenone-empagliflozin combo has superior efficacy in CKD and T2D.
Phase 3 VISIONARY trial data showed sibeprenlimab helps achieve significant proteinuria reduction in IgAN.
NKF SCM25, atrasentan for IgAN, obinutuzumab for lupus nephritis, sotagliflozin and hemoglobin, felzartamab for AMR, more.
Treatment with a finerenone-empagliflozin combo leads to greater decreases in albuminuria in CKD and type 2 diabetes.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
A study highlights the role of NPT2b in tubulointerstitial fibrosis and CKD progression.
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis.
A study assessed whether the cardiovascular and renal effects of canagliflozin are dose dependent.
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Survival benefits of deceased-donor kidney transplantation decrease when older patients receive lower quality organs.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.